The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Sexually Transmitted Infections (STIs) Market Between 2026 And 2030?
The sexually transmitted infections (stis) market has experienced rapid expansion in recent years. This market is projected to expand from $71.28 billion in 2025 to $79.48 billion in 2026, showing a compound annual growth rate (CAGR) of 11.5%. The historical growth of the market can be ascribed to an increasing prevalence of STIs, restricted availability of early diagnostic instruments, expanding government awareness initiatives, evolving urbanization and lifestyle patterns, and a surge in patient attendance at sexual health clinics.
The sexually transmitted infections (STIs) market is anticipated to experience significant expansion in the coming years, projected to reach a valuation of $126.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.4%. This forecasted growth is primarily driven by factors such as the increasing adoption of sophisticated molecular diagnostic methods, the rise of at-home STI testing solutions, greater integration with telemedicine platforms, augmented financial support for STI prevention initiatives, and the emergence of AI-powered diagnostic instruments. Key trends expected during this period encompass the creation of rapid point-of-care STI tests, a surge in the utilization of home-based STI test kits, advancements in vaccine development for STIs, wider adoption of integrated diagnostic platforms, and intensified public awareness campaigns aimed at STI prevention.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13047&type=smp
Which Key Drivers Are Affecting The Sexually Transmitted Infections (STIs) Market Development?
The sexually transmitted infections (STIs) market is anticipated to expand due to a significant rise in government initiatives aimed at increasing awareness of sexually transmitted infections. A government initiative is typically a program or policy implemented to achieve specific objectives and address particular problems. Governments offer various initiatives to prevent, control, and treat sexually transmitted infections (STIs), including funding for public education campaigns to raise awareness, vaccines for specific STIs, and free or low-cost screening and testing services. For instance, in April 2023, Springfield-Greene County Health, a US-based public health department, launched the Disease Intervention Specialist (DIS) program. This new initiative, established in partnership with the Missouri Department of Health and Senior Services (Missouri DHSS), aims to combat the increasing spread of sexually transmitted infections (STIs) in Greene County. The two specialists in the DIS program will primarily focus on syphilis and HIV, contacting individuals who test positive for these diseases, connecting them with treatment options, and assisting in identifying and informing their contacts about the infection. Consequently, the proliferation of government initiatives is expected to propel the sexually transmitted infections (STIs) market.
How Is The Sexually Transmitted Infections (STIs) Market Segmented Across Different Segment Categories?
The sexually transmitted infections (stis) market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), Gonorrhea, Syphilis, Other Types
2) By Treatment: Antibiotics, Antiviral
3) By Location Of Testing: Laboratory Testing, Point-Of-Care (POC) Testing
4) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Human Immunodeficiency Virus (HIV): HIV Type 1, HIV Type 2
2) By Human Papilloma Virus (HPV): Low-Risk HPV, High-Risk HPV
3) By Gonorrhea: Uncomplicated Gonorrhea, Complicated Gonorrhea
4) By Syphilis: Primary Syphilis, Secondary Syphilis, Tertiary Syphilis
5) By Other Types: Chlamydia, Herpes Simplex Virus (HSV), Hepatitis B, Hepatitis C, Trichomoniasis
What Trends Are Transforming The Sexually Transmitted Infections (STIs) Market?
Leading companies within the sexually transmitted infections (STIs) market are innovating products leveraging fluorescent PCR technology to secure a competitive edge. Fluorescent PCR (Polymerase Chain Reaction) technology is a molecular biology method designed to identify and quantify specific DNA sequences in biological samples. For example, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a China-based provider of molecular diagnostic solutions, unveiled two new polymer chain reaction (PCR) kits: the Mycoplasma Hominis Real-Time PCR Kit and the Treponema Pallidum Real-Time PCR Kit. These kits offer a complete PCR solution for the early diagnosis of sexually transmitted illnesses, which impact numerous individuals. The BioPerfectus Mycoplasma Hominis Real-Time PCR Kit is a reagent utilizing fluorescent PCR technology to detect Mycoplasma hominis in human male urethral swabs, female cervical or vaginal swabs, and urine specimens. Meanwhile, the BioPerfectus Treponema Pallidum Real-Time PCR Kit is designed to detect treponema pallidum nucleic acid in human serum and plasma.
Which Organizations Play A Role In The Sexually Transmitted Infections (STIs) Market Landscape?
Major companies operating in the sexually transmitted infections (stis) market are Pfizer Inc., Johnson & Johnson, Roche Holdings AG, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Wockhardt Ltd., Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd.
Get The Full Sexually Transmitted Infections (STIs) Market Report:
Which Region Leads The Sexually Transmitted Infections (STIs) Market In Terms Of Market Share?
North America was the largest region in the sexually transmitted infection (STIs) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sexually transmitted infections (stis) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Sexually Transmitted Infections (STIs) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Sexually Transmitted Infections (STIs) Market 2026, By The Business Research Company
Std Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/std-diagnostics-global-market-report
Chlamydia Infection Diagnostics Market Report
Genital Herpes Market Report
https://www.thebusinessresearchcompany.com/report/genital-herpes-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model